Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma

Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) recurrence after liver transplantation occurs in approximately 20% of patients. Most of these patients use immunosuppressant drugs. Meanwhile, patients with HCC recurrence are frequently treated with the small molecule kinase inhibitor (SMKI) sorafenib. However, sorafe...

Full description

Bibliographic Details
Main Authors: Koen G. A. M. Hussaarts, Leni van Doorn, Sander Bins, Dave Sprengers, Peter de Bruijn, Roelof W. F. van Leeuwen, Stijn L. W. Koolen, Teun van Gelder, Ron H. J. Mathijssen
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Pharmaceuticals
Subjects:
HCC
liver transplantation
sorafenib
Online Access:https://www.mdpi.com/1424-8247/14/1/46

Internet

https://www.mdpi.com/1424-8247/14/1/46

Similar Items